(Total Views: 29)
Posted On: 09/04/2025 3:55:55 PM
Post# of 51
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights CEO Dr. Vuong Trieu’s Impact and Clinical Pipeline Progress
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments, provided an update on its pipeline while recognizing the contributions of Chairman and CEO Dr. Vuong Trieu. Dr. Trieu has filed more than 500 patents and holds 75 issued patents spanning biologics, small molecules, nanoparticles and diagnostics. He co-invented and developed Abraxane (nab-paclitaxel), acquired by Celgene in a $2.9 billion transaction, and later sold Cynviloq (nanoparticle paclitaxel) to NantPharma in a $1.3 billion deal. His career achievements extend across multiple therapeutic areas with a focus on advancing first-in-class treatments for high unmet medical needs.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing oncology and immunotherapy treatments, provided an update on its pipeline while recognizing the contributions of Chairman and CEO Dr. Vuong Trieu. Dr. Trieu has filed more than 500 patents and holds 75 issued patents spanning biologics, small molecules, nanoparticles and diagnostics. He co-invented and developed Abraxane (nab-paclitaxel), acquired by Celgene in a $2.9 billion transaction, and later sold Cynviloq (nanoparticle paclitaxel) to NantPharma in a $1.3 billion deal. His career achievements extend across multiple therapeutic areas with a focus on advancing first-in-class treatments for high unmet medical needs.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
